We are live on ! Find out more
FCMI

Foresite Capital Management II Portfolio holdings

AUM $29.2M
1-Year Est. Return 44.84%
This Fund
S&P 500
This Quarter Est. Return
-2.13%
1 Year Est. Return
+44.84%
3 Year Est. Return
-66.21%
5 Year Est. Return
-36.36%
10 Year Est. Return
–
AUM
$270M
AUM Growth
-$13.7M
Cap. Flow
-$4.52M
Cap. Flow %
-1.67%
Top 10 Hldgs %
100%
Holding
10
New
–
Increased
1
Reduced
5
Closed
–

Top Buys

Rank Stock Value
1
BDSI
BioDelivery Sciences International, Inc.
BDSI
+$2.58M

Top Sells

Rank Stock Value
1
ADAP
Adaptimmune Therapeutics
ADAP
+$2.1M
2
ALDR
Alder Biopharmaceuticals
ALDR
+$1.81M
3
AIMT
Aimmune Therapeutics
AIMT
+$1.58M
4
XLRN
Acceleron Pharma
XLRN
+$1.2M
5
EPZM
Epizyme, Inc
EPZM
+$409K

Sector Composition

Rank Sector Weight
1 Healthcare 33.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AERI
1
DELISTED
Aerie Pharmaceuticals
AERI
$90.2M 33.37%
1,464,749
– –
AIMT
2
DELISTED
Aimmune Therapeutics
AIMT
$90M 33.33%
3,300,797
-55,952
-2% -$1.58M
ALDR
3
DELISTED
Alder Biopharmaceuticals
ALDR
$26.4M 9.77%
1,586,220
-100,000
-6% -$1.81M
INSM icon
4
Insmed
INSM
$23.2B
$19.6M 7.24%
967,636
– –
EPZM
5
DELISTED
Epizyme, Inc
EPZM
$15.2M 5.62%
1,432,364
-35,851
-2% -$409K
XLRN
6
DELISTED
Acceleron Pharma
XLRN
$12.6M 4.67%
220,268
-24,488
-10% -$1.2M
ADAP
7
DELISTED
Adaptimmune Therapeutics
ADAP
$6.78M 2.51%
500,000
-200,000
-29% -$2.1M
DNLI icon
8
Denali Therapeutics
DNLI
$3.67B
$5.43M 2.01%
250,000
– –
BDSI
9
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$2.66M 0.98%
949,233
+918,733
+3,012% +$2.58M
SGMO
10
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$1.36M 0.5%
80,500
– –

Similar funds

AG
Appleton Group Appleton, Wisconsin $28.6M AUM 32.21% 1-Year Est. Return
SAM
Sandbar Asset Management London, United Kingdom $30.5M AUM 46.07% 1-Year Est. Return
AC
Amia Capital London, United Kingdom $32.1M AUM 0.56% 1-Year Est. Return
QI
Qualcomm Inc San Diego, California $32.1M AUM 5.35% 1-Year Est. Return
TAAM
Top Ace Asset Management Hong Kong $25.3M AUM 23.27% 1-Year Est. Return
NAM
Nationwide Asset Management Columbus, Ohio $25.1M AUM 13.37% 1-Year Est. Return
MSKCC
Memorial Sloan Kettering Cancer Center New York $24.6M AUM 10.16% 1-Year Est. Return
BRC
Bishop Rock Capital New York $24.3M AUM 20.73% 1-Year Est. Return

Foresite Capital Management II's Q3 2018 Portfolio in Review

As of Q3 2018, Foresite Capital Management II held 10 positions worth $270M, down 4.8% from $284M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q3 2018: portfolio turnover was 0%. Foresite Capital Management II opened no new positions and made no exits, leaving the 10-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, down from 33% a quarter earlier.

  • Foresite Capital Management II added most to BioDelivery Sciences International, Inc. in Q3 2018, an estimated $2.58M increase.
  • Foresite Capital Management II's biggest Q3 2018 reduction was Adaptimmune Therapeutics, cutting an estimated $2.1M.
  • Foresite Capital Management II's ten largest holdings make up 100% of its $270M portfolio in Q3 2018.
  • Foresite Capital Management II opened 0 new positions and closed 0 in Q3 2018.
  • Foresite Capital Management II's portfolio value fell 4.8% quarter-over-quarter to $270M.

Based on Foresite Capital Management II's 13F filing for Q3 2018, filed 13 Nov 2018.